Thursday, June 5, 2025
VISIT ROYALMOK
Agarwood Times
  • Home
  • Agarwood
  • Health
  • Diseases
  • Diet & Fitness
  • Nutrition
  • Sleep Info
  • Meditation
  • Shop
No Result
View All Result
  • Home
  • Agarwood
  • Health
  • Diseases
  • Diet & Fitness
  • Nutrition
  • Sleep Info
  • Meditation
  • Shop
No Result
View All Result
Agarwood Times
No Result
View All Result

Antiviral medication for mpox no better than placebo, NIH says

August 15, 2024
in Health
Reading Time: 3 mins read
0 0
A A
0
Home Health
Share on FacebookShare on Twitter


The Nationwide Institutes of Well being stated Thursday that an antiviral typically used to deal with mpox didn’t resolve sufferers’ signs sooner than placebo in a randomized trial.

The outcomes are notable as a result of the drug, tecovirimat, has hardly ever been studied clinically for mpox, regardless of its vast use through the 2022 and 2023 outbreaks within the U.S. and Europe.

And the outcomes got here a day after the World Well being Group as soon as once more declared mpox a public well being emergency of worldwide concern, after case numbers swelled within the Democratic Republic of Congo and a number of different African international locations.  Sweden on Thursday reported an an infection in somebody who had traveled to an affected area, the primary reported case outdoors Africa within the present outbreak.

Tecovirimat, marketed as TPOXX, was accepted by the Meals and Drug Administration in 2018 for smallpox, a associated virus that’s been eradicated however stays a bioterrorism concern. Medical doctors hoped it will even be efficient for mpox, due to similarities between the 2 pathogens. However information have been largely restricted to animal research and case studies.

Within the NIH co-sponsored examine, sufferers within the Democratic Republic of the Congo, the place mpox is endemic, have been randomized to obtain both tecovirimat or placebo. All sufferers needed to stay within the hospital for therapy. Each teams noticed their signs resolve on the same time scale, though the NIH famous mortality was 1.7% throughout each teams — beneath the three.6% usually reported within the DRC — suggesting the broader, high-quality supportive care they acquired within the hospital can  save lives, even when the drug itself didn’t have an effect.

WHO declares mpox outbreak a worldwide well being emergency

“These findings are disappointing, however they offer us important info and reinforce the necessity to determine different therapeutic candidates for mpox whereas we proceed analysis on tecovirimat use in different populations with mpox,” Jeanne Marrazzo, director of the Nationwide Institute of Allergy and Infectious Ailments, stated in a press release.

There are two clades of mpox. The examine centered on clade I, which is endemic within the DRC and is taken into account to trigger extra extreme illness. The 2022 international mpox outbreak was pushed by a variant of clade II, referred to as clade IIb. Each clades have contributed to the brand new international well being emergency and might trigger painful scarring rashes, together with fever, complications, muscle aches and respiratory signs.

The 2022 outbreak unfold largely by way of sexual contact. The WHO has stated a brand new variant of clade 1, known as clade 1b, has additionally unfold by way of sexual networks, though the virus can cross by means of different types of contact.

Siga Applied sciences, the corporate that sells tecovirimat, stated in a press release that two subsets of sufferers noticed “significant enchancment”: Those that enrolled within the examine inside seven days of symptom onset and people with extreme illness.

The corporate didn’t share particular information or say whether or not these outcomes have been statistically vital. The NIH didn’t spotlight both subset in its announcement, saying solely that additional analyses have been deliberate. Siga’s inventory was down 34% on Thursday morning.

As a result of smallpox is eradicated, tecovirimat was accepted for that virus primarily based on animal research alone. In these research, animals who have been handled inside 4 or 5 days confirmed the most effective outcomes, with survival dropping to 50% for animals handled on day 6, suggesting early intervention will be important.

Two trials are ongoing to check tecovirimat in clade II mpox.

Helen Branswell contributed reporting.



Source link

Tags: AntiviralmedicationMpoxNIHplacebo
Previous Post

The Ideal Protein Alternatives (IPA) Diet: A Guide for Post-Bariatric Surgery Patients

Next Post

UK’s National Crime Agency says it is ‘not scared’ of PPE Medpro’s lawyers | Michelle Mone

Related Posts

Lucet to Acquire Home Care Company Emcara Health
Health

Lucet to Acquire Home Care Company Emcara Health

June 5, 2025
Diabetes drug shows benefits for patients with liver disease
Health

Diabetes drug shows benefits for patients with liver disease

June 4, 2025
Household environments may affect the likelihood of children developing eczema
Health

Household environments may affect the likelihood of children developing eczema

June 4, 2025
UnitedHealth accidentally emails internal talking points to reporter
Health

UnitedHealth accidentally emails internal talking points to reporter

June 5, 2025
Scripta Insights, RxSaveCard partner for lower prescription drug costs
Health

Scripta Insights, RxSaveCard partner for lower prescription drug costs

June 5, 2025
Trump’s Cognitive ‘Decline’ Suggests He ‘Might Not Make It Through Four Years,’ Republican Strategist Says
Health

Trump’s Cognitive ‘Decline’ Suggests He ‘Might Not Make It Through Four Years,’ Republican Strategist Says

June 4, 2025
Next Post
UK’s National Crime Agency says it is ‘not scared’ of PPE Medpro’s lawyers | Michelle Mone

UK’s National Crime Agency says it is ‘not scared’ of PPE Medpro’s lawyers | Michelle Mone

The Guardian view on A-level results day: great expectations have been met | Editorial

The Guardian view on A-level results day: great expectations have been met | Editorial

The state of digital health investment, part 4: Atropos Health

The state of digital health investment, part 4: Atropos Health

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

RECOMMENDED

Lucet to Acquire Home Care Company Emcara Health
Health

Lucet to Acquire Home Care Company Emcara Health

by admin
June 5, 2025
0

Lucet, a behavioral well being firm, will purchase Emcara Well being, a value-based medical group targeted on dwelling care, the...

New HHS document details deep NIH cuts as part of Trump budget request

New HHS document details deep NIH cuts as part of Trump budget request

May 31, 2025
Simple Red Wine Vinaigrette

Simple Red Wine Vinaigrette

June 2, 2025
White House Dodges AI Accusation After MAHA Report Cited Studies That ‘Appear Not to Exist’

White House Dodges AI Accusation After MAHA Report Cited Studies That ‘Appear Not to Exist’

May 30, 2025
Solicitor general urges Supreme Court not to review Oklahoma law on PBMs

Solicitor general urges Supreme Court not to review Oklahoma law on PBMs

May 30, 2025
Antibiotic Resistance, Cultivated Meat, and Our Health

Antibiotic Resistance, Cultivated Meat, and Our Health

June 3, 2025
Facebook Twitter Instagram Youtube RSS
Agarwood Times

Stay informed with the latest news, articles, and insights on agarwood cultivation, history, sustainability, and more. Explore the timeless allure of agarwood and deepen your understanding of this extraordinary natural resource.

CATEGORIES

  • Agarwood
  • Diet & Fitness
  • Diseases
  • Health
  • Meditation
  • Nutrition
  • Sleep Info
  • Uncategorized
No Result
View All Result

SITEMAP

  • About us
  • Advertise With Us
  • Disclaimer
  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms and Conditions
  • Contact us

Copyright © 2024 Agarwood Times.
Agarwood Times is not responsible for the content of external sites.

No Result
View All Result
  • Home
  • Agarwood
  • Health
  • Diseases
  • Diet & Fitness
  • Nutrition
  • Sleep Info
  • Meditation
  • Shop
VISIT ROYALMOK

Copyright © 2024 Agarwood Times.
Agarwood Times is not responsible for the content of external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In